Conditionally reprogrammed cells as a novel tool for biobanking

描述(由申请人提供)：我们最近发现的从人体组织产生细胞培养的条件重编程(CR)为生物谱库提供了新的和令人兴奋的机会。这种细胞技术使从手术标本和小活检中快速产生细胞培养成为可能，从而为遗传和蛋白质组分析提供无限数量的患者材料。然而，这项技术走得更远：它将允许对肿瘤细胞进行功能分析，并与来自同一组织的患者正常细胞进行比较。在这份提案中，我们将扩展和验证CR技术的各个方面，并优化其在生物库中的使用。重要的是要验证CR细胞的基因型和功能反应是否与原发肿瘤相似，实验将使用外显子组测序和TruSeq分析来解决这些问题。我们还将研究CR细胞是否可以预测患者对治疗的反应，正如我们最近在《新英格兰医学杂志》上对一个单一病例所描述的那样。事实上，我们相信这项技术将改变病理部门和组织储存库冷冻患者标本的方式。不是简单地快速冷冻样本用于未来的分子分析，肿瘤样本将被冷冻在低温保存剂中，这将额外允许产生用于诊断和治疗的细胞培养。 疗效评价。

DESCRIPTION (provided by applicant): Our recent discovery of conditional reprogramming (CR) to generate cell cultures from human tissues offers new and exciting opportunities for biospecimen repositories. This cell technology makes it possible to rapidly generate cell cultures from surgical specimens and small biopsies, thereby providing an unlimited amount of patient material for genetic and proteomic analysis. However, this technology goes further: it will allow the functional analysis of tumor cells and comparison with the patients' normal cells from the same tissue. In this proposal we will extend and validate aspects of the CR technology and optimize its usage for biobanking. It is important to verify that the genotype and functional responses of CR cells mimics that of the primary tumor and experiments will address these issues using exome sequencing and TruSeq analysis. We will also examine whether the CR cells can predict patient responses to therapies, as we have recently described for a single case in the New England Journal of Medicine. Indeed, we believe that this technology will alter how Pathology departments and tissue repositories freeze patient specimens. Rather than simply quick freezing samples for future molecular analysis, tumor samples will be frozen in cryopreservative, which will additionally permit the generation of cell cultures for diagnostic and therapeutic evaluation.